ReviewBiomaterials translational2025
Engineering strategies and biomedical applications of bacterial extracellular vesicles.
Review in Biomaterials translational, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bacterial extracellular vesicles as emerging biostimulants in plant microbe signaling and stress tolerance.World journal of microbiology & biotechnology · 2026Review
- [Preparation of HLYVSPW peptide-displaying outer membrane vesicles and validation of their in vitro targeting effects on triple-negative breast cancer cells].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Article
- Bacterial Extracellular Vesicles at the Crossroads of Immune Regulation and Biofilm Dynamics: Biogenesis, Comparative Analysis, and Translational Challenges.Biomolecules · 2026Review
- Bacterial extracellular vesicles: emerging players in antimicrobial resistance and clinical translation.Molecular biology reports · 2026Review
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Probiotic-Derived Extracellular Vesicles as Potential Nano-Immunotherapeutic Platforms in IBD: A Clinician's Perspective.International journal of nanomedicine · 2026Review
- The role ofJournal of oral microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial extracellular vesicles (BEVs) are emerging as promising therapeutic agents and drug delivery vehicles due to their unique properties. These nanoscale vesicles possess stable membrane structure and naturally encapsulate a variety of bioactive molecules, making them versatile tools in biomedical applications. However, clinical translation of BEVs faces challenges such as insufficient display of disease-specific antigens, excessive toxicity, and rapid clearance. Addressing these issues is crucial for the clinical translation of BEVs. In this review, we discuss recent advances in BEV engineering strategies aimed at addressing these limitations and expanding their therapeutic applications. We highlight approaches for loading exogenous cargo into BEVs, detoxification strategies, and the latest progress in the application of engineered BEVs for treating infectious diseases, cancer, and other disorders. Despite promising preclinical results, clinical translation is hindered by safety concerns, standardisation difficulties, and scalability issues. Future research should focus on optimising detoxification processes, establishing global standardisation, and improving production methods to facilitate successful clinical translation of engineered BEVs. This review provides insights into the current status and future perspectives of BEV engineering for therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.